Skip to content

COVID-19 VACCINE

We are researching for a new vaccine against COVID-19 (SARS-CoV-2)

COVID-19 VACCINE based on recombinant protein

HIPRA SARS-CoV-2 is a recombinant protein vaccine designed to optimize its safety and induce a potent immune response that neutralizes the COVID-19 virus.

COVID-19 comprehensive diagnostic service

Discover the clinical analysis service for the diagnosis of COVID-19 for health centers, occupational risk prevention services and companies. Delivery of results in less than 24 hours from the reception of the sample to our laboratory.

HIPRA’s responsibility to society

Since the start of the health crisis caused by the COVID-19, we contacted the public healthcare authorities and placed at their disposal our new diagnostic laboratory and part of our technical staff.

WHAT WE ARE DOING

HIPRA’s responsibility to society

Since the start of the health crisis caused by the COVID-19, we contacted the public healthcare authorities and placed at their disposal our new diagnostic laboratory and part of our technical staff.

KNOWLEDGE:

Our Knowledge in Diagnosing COVID-19

Learn about the main diagnostic techniques available to tackle the COVID-19 pandemic.

OUR EXPERIENCE:

HIPRA, a reference in research

We are a pharmaceutical multinational company dedicated to the research, production and marketing of vaccines and diagnostic products. We have over 60 years of market experience and 38 global subsidiaries worldwide.

For more information, contact us

Request a phone call or a commercial visit to learn about our prevention service

Contact us and we will detail our service of extraction, shipment, analysis of samples and results

Basic Personal Data Protection information:

Controller: LABORATORIOS HIPRA, S.A.
Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
Lawful basis: Performance of the contractual relationship and HIPRA’s legitimate interest.
Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

Solidly established company on an international scale:

We have our own subsidiaries in 39 countries and a distribution network that enables our products and services to reach customers in more than 100 countries

We have evolved to be stronger:

At HIPRA we’ve gone one step forward with the incorporation of our Human Health division. This, together with the Animal Health division will allow us to continue developing solutions that improve human and animal health.

We've evolved

With a history of more than 50 years behind us, at HIPRA we’ve always been at the forefront of change. We’ve adapted to social and technological changes, and our desire to be innovative has made us referents in prevention.

Thanks to the experience acquired over the years and to our extensive work in the field of animal health, we at HIPRA have evolved to be stronger, to build immunity for a healthier world.

At HIPRA we’ve gone one step forward with the incorporation of our Human Health division that, together with Animal Health, will allow us to explore new horizons. To do so, we have developed an updated singular brand that looks to the future.

Building immunity for a healthier world

HIPRA’s new claim, “Building immunity for a healthier world”, captures our reason for existence: to innovate constantly with the aim of producing solutions that improve human and animal health.

This evolution is possible thanks to the HIPRA people, a talented and enthusiastic multicultural team that every day is able to develop the best solutions for all our worldwide clients.